Tag Archives: conference coverage

Hormone replacement therapy may increase the risk of ulcerative colitis in postmenopausal women

mdCurrent Conference Report: Digestive Disease Week Hormone replacement therapy (HRT) may increase the risk of ulcerative colitis in postmenopausal women, according to a new study presented at Digestive Disease Week 2012. “It is important that clinicians are aware of the results of this study, but it should not lead to… 

Read more »
Posted in Gastroenterology, mdCurrent Conference Reports, Pharmacology, Primary Care, Women's Health | Also tagged , , , , , , , , , , | Volume: | 1 Response

Early therapy delays progression to clinically definite multiple sclerosis

mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting Data from 2 major phase 3 trials have demonstrated that progression to clinically definite multiple sclerosis (MS) can be prevented or delayed with early rather than delayed therapy. Two regimens of subcutaneous interferon beta-1a (IFNb) were evaluated in patients who… 

Read more »
Posted in mdCurrent Conference Reports, Neurology, Pharmacology | Also tagged , , , , , , , , , | Volume: | Leave a comment

Continuous intestinal infusion of levodopa-carbidopa gel shows benefit in advanced Parkinson’s disease

mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting A novel strategy to reduce the motor complications associated with fluctuating blood levels of levodopa in patients with Parkinson’s disease was associated with clinically meaningful improvements in disease control, according to the authors of a double-blind trial. Undertaken in patients… 

Read more »
Posted in mdCurrent Conference Reports, Neurology, Pharmacology | Also tagged , , , , , | Volume: | Leave a comment

First oral disease modifying therapy for multiple sclerosis challenges injectables in long-term data

mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting Follow-up data out to 24 months for the first oral disease modifying therapy (DMT) licensed for treatment of multiple sclerosis (MS) continues to suggest that the efficacy and safety rivals that of the injectable agents that have been the MS… 

Read more »
Posted in mdCurrent Conference Reports, Neurology, Pharmacology | Also tagged , , , , , , | Volume: | Leave a comment